Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. Cavalieri S, et al. Among authors: lenoci d. Cells. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176. Cells. 2022. PMID: 36231138 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35303067
MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures.
Corti A, De Cecco L, Cavalieri S, Lenoci D, Pistore F, Calareso G, Mattavelli D, de Graaf P, Leemans CR, Brakenhoff RH, Ravanelli M, Poli T, Licitra L, Corino V, Mainardi L. Corti A, et al. Among authors: lenoci d. Biomark Res. 2023 Jul 16;11(1):69. doi: 10.1186/s40364-023-00494-5. Biomark Res. 2023. PMID: 37455307 Free PMC article.
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
Pesenti C, Beltrame L, Velle A, Fruscio R, Jaconi M, Borella F, Cribiù FM, Calura E, Venturini LV, Lenoci D, Agostinis F, Katsaros D, Panini N, Bianchi T, Landoni F, Miozzo M, D'Incalci M, Brenton JD, Romualdi C, Marchini S. Pesenti C, et al. Among authors: lenoci d. Eur J Cancer. 2022 Aug;171:85-95. doi: 10.1016/j.ejca.2022.05.005. Epub 2022 Jun 14. Eur J Cancer. 2022. PMID: 35714451 Free article.
Claudin-1 in Head and Neck Squamous Cell Carcinoma.
Cavalieri S, Bergamini C, Lenoci D, Ottini A, Lucchetta M, Torchia E, Licitra L, De Cecco L. Cavalieri S, et al. Among authors: lenoci d. Oncology. 2024 Aug 14:1-5. doi: 10.1159/000540775. Online ahead of print. Oncology. 2024. PMID: 39231459 Free article.
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Serafini MS, et al. Among authors: lenoci d. J Immunother Cancer. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. J Immunother Cancer. 2024. PMID: 38290766 Free PMC article. Clinical Trial.
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial.
Cavalieri S, Bruno E, Serafini MS, Lenoci D, Canevari S, Lopez-Perez L, Hernandez L, Mariani L, Miceli R, Gavazzi C, Pasanisi P, Rosso E, Cordero F, Bossi P, Golusinski W, Dietz A, Strojan P, Fuereder T, De Cecco L, Licitra L. Cavalieri S, et al. Among authors: lenoci d. Front Oncol. 2024 Jan 4;13:1321174. doi: 10.3389/fonc.2023.1321174. eCollection 2023. Front Oncol. 2024. PMID: 38239654 Free PMC article.
21 results